

## Phages prevent biofilm formation on catheters under flow

**Hoda Bseikri**<sup>1</sup>, Slawomir Michniewski<sup>2</sup>, Eduardo Goicoechea Serrano<sup>3</sup>, Eleanor Jameson<sup>4</sup>

<sup>1</sup>School of Life Sciences, Gibbet Hill Campus, The University of Warwick, Coventry CV4 7AL

<sup>2</sup>Dept Genetics and Genome Biology, University of Leicester, Leicester, LE1 7HA, UK

<sup>3</sup>Warwick Integrative Synthetic Biology Centre and School of Life Sciences, Gibbet Hill Campus, The University of Warwick, Coventry CV4 7AL

<sup>4</sup>School of Natural Sciences, Bangor University, Gwynedd, LL57 2TH

Corresponding author: Eleanor Jameson, [E.Jameson@bangor.ac.uk](mailto:E.Jameson@bangor.ac.uk), School of Natural Sciences, Bangor University, Gwynedd, LL57 2TH

## Abstract

Biofilms pose a significant challenge in medical settings, leading to persistent infections. Phage therapy has shown promise in biofilm eradication, but its effectiveness under dynamic flow conditions remains unclear. Here we use two novel phages isolated on *Klebsiella*, Llofrudd and Samara, and characterized their genomes, host range and virulence. In this study, we built a simple catheterised bladder model with flow to investigate the impact of phage treatment on biofilm viability in a flow-based catheter model. Our analyses demonstrate that phages Llofrudd and Samara are the same species and infect a limited number of strains (3/222), but across three species: *Klebsiella aerogenes*, *Klebsiella pneumoniae* and *E. coli*. Phage treatment significantly reduced *E. coli* biofilm viability in catheters both in static conditions and under flow, highlighting the potential of phage therapy as an intervention strategy for catheter associated urinary tract infections (CAUTI).

## Introduction

The use of indwelling catheters is common in health care settings, yet there is a risk of catheter associated urinary tract infections (CAUTIs) (Nicolle, 2014). Approximately 86% of hospital patients undergoing operations require indwelling catheters, with the cost of catheter use, management and CAUTIs estimated to be £1-2.5 billion per annum in the National Health Service (Feneley *et al.*, 2015). CAUTIs accounted for >17% of healthcare acquired infections making them the third most common infection in these settings (Zarb *et al.*, 2012). CAUTIs can develop into life-threatening complications such as pneumonia, bacteraemia or sepsis (Jacobsen *et al.*, 2008), and are associated with extended stays (Green *et al.*, 1982) and medical costs (Hollenbeck and Schilling, 2018). Around 1-4% of CAUTIs develop into bacteraemia, which has a fatality rate of ~13 % (Bryan and Reynolds, 1984). The use of indwelling catheters is common practice in the medical field, with long-term catheters being used for up to three months (Hall *et al.*, 2020). However, prolonged catheter use risks bacteria forming biofilms on the catheter, which increases the risk of patients developing a CAUTI (Al-Hazmi, 2015; Clayton, 2017; Cortese *et al.*, 2018).

A further complication of bacterial infections is antimicrobial resistance (AMR), which is increasing and poses a significant global threat to public health (O'neill, 2014; Zarb *et al.*, 2012). In 2019, ~ 4.8 million deaths were associated with AMR (Murray *et al.*, 2022), and hospital-associated AMR infections and deaths rose a further 15% during 2020 (Centers for Disease Control and Prevention, 2022). The two most prevalent causes of CAUTIs, *Escherichia coli* (*E. coli*) and *Klebsiella* (Gul *et al.*, 2021), have been identified as key priority pathogens for the development of new antimicrobials by the World Health Organization due to widespread AMR associated with them (Tacconelli *et al.*, 2018, 2017). Both *E. coli* and *Klebsiella* readily form biofilms on catheters, making them even more recalcitrant to antimicrobials (Hidron *et al.*, 2008; Jacobsen *et al.*, 2008; Sabir *et al.*, 2017; Wazait *et al.*, 2003). These biofilms can form under different nutrient conditions and flow levels, and once formed are hard to remove (Melo and Vieira, 1999). The increasing prevalence of AMR and biofilm formation in CAUTIs makes the need for alternative or complementary treatments to existing antibiotics critical (Gul *et al.*, 2021; Marantidis and Sussman, 2023). Bacteriophages (phages for short) represent an alternative approach with the potential to treat or prevent AMR bacterial infections, including CAUTIs (Chegini *et al.*, 2021; Lehman and Donlan, 2015; Milo *et al.*, 2017; Townsend *et al.*, 2020).

Phage therapy has been successfully used to treat patients with a range of bacterial infections with little or no adverse side effects (Bruttin and Brussow, 2005; El Haddad *et al.*, 2019). This illustrates the promise of phages for medical applications, but they are not yet a standard treatment and more focussed research is required for a variety of infections, including urinary tract infections (UTIs). Studies have demonstrated that phages can be readily isolated against UTI causing bacteria and have potential to treat and prevent UTIs (Chegini *et al.*, 2021; Lehman and Donlan, 2015; Melo *et al.*, 2016; Milo *et al.*, 2017; Townsend *et al.*, 2020). One mode of delivery is to coat catheters with phages, as a prophylaxis against the most common and problematic CAUTIs (Curtin and Donlan, 2006; Milo *et al.*, 2017; Townsend *et al.*, 2020). For phages to be successfully used in catheters we need to understand how well they perform in the conditions experienced in catheters; previously phages have been tested on catheter material and in artificial urine (Townsend *et al.*, 2020). The efficacy of phages in dynamic flow conditions, such as shear-stress of urine

flow encountered in catheters, remains poorly understood (*MacCallum et al., 2015; Ramstedt et al., 2019*). In this study we developed and tested a simple, cheap bladder model with the aim to investigate if phages can reduce CAUTI biofilm viability in a flow-based catheter model.

## Materials and Methods

### Phage strains

The phages used in the study were the closely related phages vB\_KaS-Llofrudd and vB\_KaS-Samara (the phages will be referred to as Llofrudd and Samara respectively from this point forwards). Both phages were isolated from cow slurry on *Klebsiella aerogenes* DSM 30053. The phages have a siphovirus-like morphology. Llofrudd and Samara were chosen for their efficacy against both the *Klebsiella* host of isolation and a tractable non-pathogenic reference strain of *E. coli* as a test case to establish the model system.

### Genome sequencing and annotation

Phage genomes were sequenced by MicrobesNG (Birmingham, UK) using Illumina sequencing platform. Trimmed reads were assembled de-novo using SPAdes v3.10.1 (Bankevich *et al.*, 2012). Assembled phage genomes were annotated with Prokka v1.14.6 (Seemann, 2014) using the PHROGS database (Terzian *et al.*, 2021). The genomes of Llofrudd and Samara were compared against INPHARED (Cook *et al.*, 2021) database of known phage genomes to identify their closest relatives using MASH (Ondov *et al.*, 2016) with “dist -d 0.15” option. Subsequently, their intergenomic similarities were calculated and putative species and genera clusters were determined using VIRIDIC (Moraru *et al.*, 2020).

### Bacterial strains and host range

Spot testing was carried out against 148 *Klebsiella* spp strains, 125 of which were of clinical origin and 23 reference strains from commercial collections (the species included were *K. aerogenes*, *K. pneumoniae*, *K. oxytoca*, *K. variicola*, *K. michiganensis* and *K. quasipneumoniae*), and 74 *E. coli*, 71 of which were of clinical origin and 3 reference strains, to determine the host range of phages Llofrudd and Samara, following the method described previously (Townsend *et al.*, 2021). Briefly phage stock solutions were serially diluted to  $1 \times 10^{-7}$ , and 5  $\mu\text{L}$  of each dilution was spotted onto a 0.4% overlay agar bacterial lawn, followed by overnight incubation at 37 °C. Zones of bacterial lawn clearing, indicating cell lysis, were recorded with particular attention to visible plaques.

The bacteria carried forwards for use in the biofilm experiments is the non-pathogenic bacteria *Escherichia coli* K12 MG1655 (referred to as *E. coli* K12 from this point on) (Blattner *et al.*, 1997).

### Phage virulence index

The virulence index (VP) of phages Llofrudd and Samara was calculated (Storms *et al.*, 2020). A high titre phage lysate was prepared and used as reference throughout the study. Briefly, *E. coli* K12 cultures in the exponential growth phase were adjusted by dilution to an optical density equivalent to  $1 \times 10^8$  colony forming units/ml (CFU/mL) in LB. Phages were serially diluted in a 96 well plate from  $1 \times 10^8$  to 10 plaque forming units/ml (PFU/ml) in 100  $\mu\text{L}$  volumes. To this 100  $\mu\text{L}$  of the adjusted *E. coli* K12 culture was added, resulting in multiplicity of infections (MOIs) from 1 to  $10^{-7}$ . MOI is a parameter that describes the phage to bacteria ratio. The 96 well plate was transferred to the plate reader at 37 °C with shaking, the optical density of each well was read at 600 nm every 5 min for 18 h.

The area under the curve of the resulting growth curves at each MOI was calculated from infection to the exponential growth stage. For each MOI the VP was calculated following the method (Storms *et al.*, 2020) in RStudio (version 1.1.463). VP is a measure of the phage

virulence against a bacterium, on a 0–1 scale (0 = no impact on bacterial growth, to 1, instant complete killing).

#### *Phage quantification*

Phages were quantified by plaque assays as previously described (Townsend *et al.*, 2021). Briefly, serial dilutions of the phages were made. Then 50 µl of each phage dilution was mixed with 500 µl of logarithmic growth phase *E. coli* K12 (approximately OD<sub>600nm</sub> 0.2) and incubated at room temperature for 10 min. To this mix 2.5 mL of hand-warm, molten LB agar (0.5% weight/volume, supplemented with 5 mM CaCl<sub>2</sub>) was added and mixed by swirling. Mixed agar was overlayed onto 1% LB agar plates. After setting the overlay agar plates were inverted and incubated at 37°C overnight. Plaques were counted and the titre of was presented as the number of PFU/ml.

To quantify plaques from catheters the plaque assay was adapted. For this, 1 cm long catheter segments were incubated with 500 µl logarithmic phage *E. coli* K12 for 10 min. The catheter segments were removed, 2.5 mL of hand-warm, molten LB agar (0.5%) was added and mixed by swirling. The above procedure for making the overlay plates was then followed.

#### *Biofilm growth in static 96 well plates*

Biofilms grown in cell culture plates were used as a simple, *in vitro* model to assess the ability of *E. coli* K12 to form biofilms and the ability of phages to inhibit biofilm formation and biofilms. *E. coli* cultures were standardised to  $1 \times 10^6$  CFU/mL in LB. Biofilms were grown in 96-well flat bottom cell culture treated plate (CytoOne Plate, Starlab, UK), 100 µL of standardised *E. coli* culture was added. For the treatments 100 µl of phage lysate at MOIs of 0.1, 1 and 10 was added to the *E. coli* culture. To produce the phage stocks at different MOIs, high titre phage lysates were diluted in LB media (i.e. the phage stock for MOI 0.1 =  $1 \times 10^5$  PFU/mL, MOI 1 =  $1 \times 10^6$  PFU/mL and MOI 10 =  $1 \times 10^7$  PFU/mL). For the treatments, biofilms were grown in the presence of either phage Llofrudd and Samara, positive controls with no phage treatment and negative controls containing phage alone, were included. To form a biofilm, the plates were incubated statically for 24 h at 37 °C. After 24 h, biofilm viability had stabilised and considered mature. All tests were carried out in technical triplicate, on three occasions for biological replicates.

#### *Biofilm growth in static catheters*

The catheters used in this study were Foley silicone catheters, 18fg 5/30ml balloon urinary catheters (Medisave). To grow biofilms in catheters under static conditions two methods were used.

The protocol for the growth of biofilm on catheters under static conditions was based on the method we previously described (Townsend *et al.*, 2020). Briefly, 1 cm catheters segments were incubated aerobically in 10 ml LB cultures *E. coli* at OD 0.6 for 2 hr with shaking. These catheters were then transferred to 24 well culture plates containing 2ml of LB media and incubated overnight at 37 °C. For the phage treated group, 100 µl of phage lysates  $1 \times 10^6$  pfu/ml was added to the wells. The negative control contained phage lysates alone. All tests were carried out in technical triplicate, with three biological replicates.

#### *Catheterised bladder model*

A simple catheterised bladder model was constructed using readily available lab consumables, as shown in Figure 1. To represent the bladder a 50 ml falcon tube was used. This bladder is fed with media through a media inlet consisting of a silicone tube inserted into the lid of the falcon tube. A 10 cm foley catheter segment (18fg 5/30ml balloon urinary catheters, Medisave) was inserted through a hole in the bottom of the falcon tube, and protruded 5 cm into the falcon tube. At the 35 ml graduation on the falcon tube a side inlet was inserted, consisting of a 5 cm segment of silicone tube to allow the addition of bacteria and phages to the catheterised bladder, this was clamped when not in use. All inlets and outlets were drilled, and tubing or catheter segments were inserted before autoclave sterilisation. Following sterilisation the tubing was glued in place using a hot melt adhesive (Power Adhesives 240-12-300-CRP-TP16-RS).

The catheterised bladder model shown in figure 1 allows the falcon tube bladder to fill with media until it covers the top of the catheter before media will flow through the catheter, mimicking the emptying of a bladder. The bottom of the falcon tube with the catheter segment was placed in a 1 L waste bottle and sealed with parafilm to maintain sterile conditions.

#### *Under-flow biofilms*

Under-flow biofilms were grown in catheter segments in the catheterised bladder model (fig. 1). Prior to inoculation LB media was pumped through the system for 1 hr at a rate of 3 ml/min. Bacterial biofilms were established as follows: the catheter was filled with 20 ml *E. coli* K12 inoculum in LB at  $1 \times 10^6$  CFU/ml. The inoculum was incubated in the catheter for 2 hr under static conditions to establish a colonising biofilm. For the treatments, following static bacterial incubation, 20 ml of filtered phage lysate at  $1 \times 10^6$  PFU/ml or LB media (for the no phage control) was injected through the side inlet of the bladder model. The phages were incubated for 10 min, under static conditions to enable phage-bacteria interactions (mimicking a phage treatment or coating on the catheters). Initiating LB media flow through the bladder model and catheter. Flow rate was maintained at 3 ml/min using a 323S Drive peristaltic pump (Watson-Marlow Ltd). Phages Llofrudd and Samara were applied as treatments in parallel catheterised bladder models. All under-flow biofilms were grown for 24 hrs. All tests were carried out in technical quadruplet, with three biological replicates.

#### *Biofilm viability analysis*

To quantify actively respiring cells in biofilms, the resazurin assay was used. Before carrying out the assay media was removed from the biofilms by pipetting, then the biofilm was washed twice with phosphate buffered saline. An aliquot (200  $\mu$ l in 96 well plates or 2 ml for catheter sections) of 10 mg/ml resazurin solution was added to the biofilms and then incubated at 37 °C. The end point was determined when the positive control (*E. coli* K12 only) changed from blue to pink. When the end point was reached the absorbance of the resazurin solution was measured at 570 nm and 600 nm to calculate the percentage biofilm viability.

For the under-flow catheter biofilm experiments; following 24 hr of biofilm growth in catheterised bladder model, the catheter was extracted and cut into 1 cm sections to assess biofilm viability, both 1 cm end sections were discarded due to variability in biofilm formation.

## Results

### Host range

The host range was generated against the clinical and reference panel. Both phages Llofrudd and Samara infected and produced plaques in 2/148 *Klebsiella* spp. and 1/74 *E. coli*. The strains were: reference strain *Klebsiella aerogenes* 30053, clinical isolate *K. pneumoniae* WALES42 and reference strain *E. coli* K12. The reference strain *E. coli* K12 was selected as the host for all experiments from this point forwards because it is non-pathogenic, which was important when developing a flow-based system due to potential containment and spill risks.

### Phage virulence index

The virulence index for Llofrudd was 0.54, and Samara had a value of 0.56.

### Sequencing

The reconstructed genome size of Llofrudd was 49,702 bp and Samara was 49,646 bp. Genomes have been uploaded to the deposited in the ENA under the accessions OY639338 and OY639337, respectively. Both phages Llofrudd and Samara showed >99.9 % MASH similarity to each other and to vB\_KaS-Ahsoka (accession LR881108), vB\_KaS-Gatomon (LR881110) and vB\_KppS-Samwise (LR881107), and >79 % MASH similarity to *Escherichia* phage Henu7 (MN019128), *Enterobacter* phage N5822 (MW032452), *Escherichia* phage IsaakIselin (MZ501077) and *Escherichia* phage JohannLBurckhardt (MZ501085). VIRIDIC analysis results at 70 % intergenomic similarity cutoff indicated that these phages belong to the same genus: *Henuseptimavirus* (Family *Drexlerviridae*, Subfamily *Tempevirinae*). However, only phages Llofrudd, Samara, Gatomon, Ahsoka and Samwise were clustered together at >95% intergenomic similarity, indicating that they belong to a separate, yet unclassified phage species in the defined *Henuseptimavirus* genus represented by Henu7 (table1) (Moraru et al., 2020).

### Phage treatment of biofilms grown under static conditions

Phages reduced biofilm viability in both 96 well plates and on static catheters (Fig. 2). In the 96 well plate grown biofilms, the biofilms grown with both phages Llofrudd and Samara had lower viability than the no phage controls. When phages were supplied at an MOI = 10, the highest concentration of phage to bacteria a small decrease from 81 % in the control to 64 % with Llofrudd and 50 % with Samara was observed (Fig 2A). At lower MOI of 1 and 0.1 a greater decrease with phage treatments were observed, ~ 30 % biofilm viability was observed for all the phage treatments, compared to the control ~ 80 % (Fig S1A). A similar pattern was observed on the statically incubated catheter segments, biofilm viability was lower in the phage treatments < 40 % for the phage treatments, compared to the control ~ 80 % (Fig S1B).

### Flow model

The flow model was successfully run for three independent experiments that formed the biological triplicates. Flow was maintained throughout the experiment and a biofilm was able to form. The variation in biofilm viability observed in the catheter segments was higher than observed in the static catheter experiments, indicating that the shear force created by the continuous flow of media may have impacted biofilm distribution (fig. 3).

### *Phage treatment of the catheterised bladder model biofilms under-flow*

Phages significantly reduced biofilm viability on catheters where flow was introduced (fig. 3). The catheters with the addition of either phage Llofrudd or Samara had statistically lower viability than the no phage controls; ~ 40 % biofilm viability was observed when phage Llofrudd was added, this figure was even lower for Samara ~ 30 % viability, compared to the no phage controls that had ~ 70 % viability (fig 3).

## **Discussion**

We observed that phage treatment with Llofrudd and Samara significantly reduced biofilm viability, with a greater reduction seen in static conditions (50 % reduction) compared to under continuous flow with a bladder reservoir (30 % reduction). This supports a previous study that have demonstrated the ability of phages to prevent biofilm formation under flow (Lehman and Donlan, 2015). However, our findings show that flow affected the extent of biofilm-reduction by phages, indicating the importance of considering the role of urine flow dynamics when optimising phages application for preventing and treating catheter-associated urinary tract infections (CAUTIs). Urine flow can influence the distribution of bacteria and biofilms along the catheter surface (Ganderton et al., 1992; Melo and Vieira, 1999). Shear forces generated by flow can disrupt biofilm formation (Tsagkari et al., 2022) and potentially enhance the accessibility of phages to target bacterial cells within the biofilm matrix. Our study observed more variation in biofilm viability in catheters under flow than static conditions, indicating the potential impact of flow on biofilm distribution. These findings suggest that phage therapy, combined with appropriate urine flow management, could be an effective strategy to prevent and treat CAUTIs, reducing patient discomfort, hospitalization duration, and healthcare costs.

Furthermore, our study highlights the ability of phages isolated on *Klebsiella aerogenes* to infect and prevent biofilm formation in another genera, *Escherichia*. Although we have only used single phages in this study, it indicates that the application of *Klebsiella* phages to prevent CAUTI, may also reduce *E. coli* infections. Our previous work has demonstrated the importance of using phage cocktails rather than single phage treatments (Townsend et al., 2020). The combination of multiple phages, with different specificities could enhance the overall efficacy of phages under flow in catheters (Lehman and Donlan, 2015). It will be important to run tests for longer (1 - 7 days, the cut off for short-term catheter use (Al-Hazmi, 2015; Hall et al., 2020)) to optimise dose and application methods for phages, particularly as low concentrations of phage treatment can initiate biofilm proliferation through stress induced systems in host bacteria (Fernandez et al., 2017).

A simple bladder model built from cheap, readily available laboratory supplies is and effective way to test CAUTIs *in vitro* and introduce flow. Our study demonstrates its applicability for testing antimicrobials in catheters to prevent CAUTIs. The model can be housed in existing incubators and needs very little equipment to study the impact of flow dynamics on catheter biofilms in the context of treatment efficacy. By utilizing our bladder model and building upon these findings, researchers can develop more effective strategies for preventing and managing UTIs, ultimately improving patient outcomes. This simple bladder model allowed us to investigate the interplay between flow, phage treatment, and biofilm viability, to provide insights into the development of effective clinical interventions.

## Conclusions

Our study demonstrates the effectiveness of phage treatment in reducing biofilm viability in both static and flow-based catheter models. Our bladder model provides a practical tool for researching CAUTI, allowing investigation of factors influencing biofilm development and treatment. Phages Llofrudd and Samara, despite the small number of hosts they infect can infect different species and genera. This underscores the importance of considering flow dynamics and phage choice on CAUTI biofilm formation. Our study highlights the value of phage therapy and the bladder model in advancing CAUTI research and driving innovation in UTI management.

## Figure and table legends

Figure 1. Diagram of the catheterised bladder model, used to test phage treatments on bacterial biofilms in urinary catheters under flow. Media was added by continuous flow at 3ml/min (as indicated by the flow direction arrow) through the media inlet, the side inlet was used for the addition of bacteria and phage, the catheter at the base of the falcon tube allows drainage of the media through the catheter to waste.

Figure 2 Phage treatments reduce the biofilm viability of *E. coli* K12 under static conditions: **A.** Grown in 96 well plates; the phages vB\_KaS-Llofrudd (Llofrudd) and vB\_KaS-Samara (Samara) were added at the beginning of biofilm formation at multiplicity of infections (MOI) 10, 1 and 0.1, as indicated on the X-axis. **B.** Grown on foley catheters; phages Llofrudd and Samara were added at the beginning of biofilm formation at a concentration of  $1 \times 10^6$  PFU/ml. The first two grey bars represent phage addition treatments, either phage Llofrudd or Samara the third black bar represents *E. coli* K12 with no phage added (No phage control). All biofilms were grown for 24 hr at 37 °C under with or without phage treatments. Bars represent the mean of three biological replicates, in technical triplicate and error bars represent the standard error of mean.

Figure 3. Phage treatments reduce the biofilm viability of *E. coli* K12 grown under flow in the catheterised bladder model. The biofilms were grown for 24 hr at 37 °C under a continuous flow rate of 3 ml/min with or without phage treatments. The first two grey bars represent phage addition treatments, using either vB\_KaS-Llofrudd (Llofrudd) or vB\_KaS-Samara (Samara) as labelled, the third black bar represents *E. coli* K12 with no phage added (No phage control). Brackets with the associated symbols denote significant differences (t-test) compared to the positive control, \*\* denotes  $p$  value  $\leq 0.01$ , \*\*\*\*  $p$  value  $\leq 0.0001$ . Bars represent the mean of three biological replicates, with four technical replicates and error bars represent the standard error of mean.

Table 1 Phage ANI similarity to the closest sequenced phage genome available calculated by VIRIDIC (Moraru *et al.*, 2020).

## CRediT authorship contribution statement

**Hoda Bseikri:** Methodology, Investigation, Writing – original draft, Visualization. **Slawomir Michniewski:** Sequencing, Bioinformatics, Writing - review & editing. **Eduardo Goicoechea Serrano:** Phage characterisation, Funding acquisition. **Eleanor Jameson:** Conceptualization, Writing, Visualization, Supervision, Funding acquisition.

### **Declaration of competing interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### **Acknowledgements**

This work was supported by a Warwick Integrative Synthetic Biology (WISB) early career fellowship, funded jointly by BBSRC/EPSRC, grant ref: BB/M017982/1 under the UK Research Councils' Synthetic Biology for Growth programme, and the Warwick Flexible Talent Mobility Award, funded by BBSRC grant ref: BB/S507982/1.

## References

Al-Hazmi, H., 2015. Role of duration of catheterization and length of hospital stay on the rate of catheter-related hospital-acquired urinary tract infections. *Res. Rep. Urol.* 41–47. <https://doi.org/10.2147/rru.s75419>

Bankevich, A., Nurk, S., Antipov, D., Gurevich, A.A., Dvorkin, M., Kulikov, A.S., Lesin, V.M., Nikolenko, S.I., Pham, S., Prjibelski, A.D., Pyshkin, A.V., Sirotkin, A.V., Vyahhi, N., Tesler, G., Alekseyev, M.A., Pevzner, P.A., 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19, 455–77. <https://doi.org/10.1089/cmb.2012.0021>

Blattner, F.R., Plunkett III, G., Bloch, C.A., Perna, N.T., Burland, V., Riley, M., Collado-Vides, J., Glasner, J.D., Rode, C.K., Mayhew, G.F., 1997. The complete genome sequence of *Escherichia coli* K-12. *science* 277, 1453–1462. <https://doi.org/10.1126/science.277.5331.1453>

Bruttin, A., Brussow, H., 2005. Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother* 49, 2874–8. <https://doi.org/10.1128/aac.49.7.2874-2878.2005>

Bryan, C.S., Reynolds, K.L., 1984. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. *J. Urol.* 132, 494–497. [https://doi.org/10.1016/s0022-5347\(17\)49707-2](https://doi.org/10.1016/s0022-5347(17)49707-2)

Centers for Disease Control and Prevention, 2022. COVID-19: US impact on antimicrobial resistance, special report 2022. Atlanta GA US Dep. Health Hum. Serv. Cent. Dis. Control Prev.

Chegini, Z., Khoshbayan, A., Vesal, S., Moradabadi, A., Hashemi, A., Shariati, A., 2021. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review. *Ann. Clin. Microbiol. Antimicrob.* 20, 1–13. <https://doi.org/10.1186/s12941-021-00433-y>

Clayton, J.L., 2017. Indwelling urinary catheters: a pathway to health care-associated infections. *AORN J.* 105, 446–452. <https://doi.org/10.1016/j.aorn.2017.02.013>

Cook, R., Brown, N., Redgwell, T., Rihtman, B., Barnes, M., Clokie, M., Stekel, D.J., Hobman, J., Jones, M.A., Millard, A., 2021. INfrastructure for a PHAge REference Database: Identification of Large-Scale Biases in the Current Collection of Cultured Phage Genomes. *PHAGE* 2, 214–223. <https://doi.org/10.1089/phage.2021.0007>

Cortese, Y.J., Wagner, V.E., Tierney, M., Devine, D., Fogarty, A., 2018. Review of catheter-associated urinary tract infections and in vitro urinary tract models. *J. Healthc. Eng.* 2018. <https://doi.org/10.1155/2018/2986742>

Curtin, J.J., Donlan, R.M., 2006. Using bacteriophages to reduce formation of catheter-associated biofilms by *Staphylococcus epidermidis*. *Antimicrob. Agents Chemother.* 50, 1268–1275. <https://doi.org/10.1128/aac.50.4.1268-1275.2006>

El Haddad, L., Harb, C.P., Gebara, M.A., Stibich, M.A., Chemaly, R.F., 2019. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. *Clin. Infect. Dis.* 69, 167–178. <https://doi.org/10.1093/cid/ciy947>

Feneley, R.C., Hopley, I.B., Wells, P.N., 2015. Urinary catheters: history, current status, adverse events and research agenda. *J. Med. Eng. Technol.* 39, 459–470. <https://doi.org/10.3109/03091902.2015.1085600>

Fernandez, L., Gonzalez, S., Campelo, A.B., Martinez, B., Rodriguez, A., Garcia, P., 2017. Low-level predation by lytic phage phiPLA-RODI promotes biofilm formation and triggers the stringent response in *Staphylococcus aureus*. *Sci Rep* 7, 40965. <https://doi.org/10.1038/srep40965>

Ganderton, L., Chawla, J., Winters, C., Wimpenny, J., Stickler, D., 1992. Scanning electron microscopy of bacterial biofilms on indwelling bladder catheters. *Eur. J. Clin. Microbiol. Infect. Dis.* 11, 789–796. <https://doi.org/10.1007/bf01960877>

Green, M.S., Rubinstein, E., Amit, P., 1982. Estimating the effects of nosocomial infections on the length of hospitalization. *J. Infect. Dis.* 145, 667–672. <https://doi.org/10.1093/infdis/145.2.667>

Gul, A., Khan, M., Ali, M., Shuaib, S.L., Sahar, S., 2021. Catheter Associated Urinary Tract Infection: Characterization of Bacterial Pathogens and their Antimicrobial Susceptibility Pattern at Two Major Tertiary Care Hospitals. *Int. J. Pathol.* 194–199.

Hall, S.J., Harrison, S., Harding, C., Reid, S., Parkinson, R., 2020. British Association of Urological Surgeons suprapubic catheter practice guidelines—revised. *BJU Int.* 126, 416–422. [https://doi.org/10.1111/j.1464-410x.2011.10303\\_2.x](https://doi.org/10.1111/j.1464-410x.2011.10303_2.x)

Hidron, A.I., Edwards, J.R., Patel, J., Horan, T.C., Sievert, D.M., Pollock, D.A., Fridkin, S.K., 2008. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. *Infect. Control Hosp. Epidemiol.* 29, 996–1011. <https://doi.org/10.1086/591861>

Hollenbeak, C.S., Schilling, A.L., 2018. The attributable cost of catheter-associated urinary tract infections in the United States: A systematic review. *Am. J. Infect. Control* 46, 751–757. <https://doi.org/10.1016/j.ajic.2018.01.015>

Jacobsen, S.M., Stickler, D.J., Mobley, H.L., Shirtliff, M.E., 2008. Complicated catheter-associated urinary tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clin. Microbiol. Rev.* 21, 26–59. <https://doi.org/10.1128/cmr.00019-07>

Lehman, S.M., Donlan, R.M., 2015. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. *Antimicrob Agents Chemother* 59, 1127–37. <https://doi.org/10.1128/aac.03786-14>

MacCallum, N., Howell, C., Kim, P., Sun, D., Friedlander, R., Ranisau, J., Ahanotu, O., Lin, J.J., Vena, A., Hatton, B., 2015. Liquid-infused silicone as a biofouling-free medical material. *ACS Biomater. Sci. Eng.* 1, 43–51. <https://doi.org/10.1021/ab5000578>

Marantidis, J., Sussman, R.D., 2023. Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways. *Infect. Drug Resist.* 1391–1405. <https://doi.org/10.2147/idr.s382617>

Melo, L., Vieira, M., 1999. Physical stability and biological activity of biofilms under turbulent flow and low substrate concentration. *Bioprocess Eng.* 20, 363–368. <https://link.springer.com/article/10.1007/s004490050604>

Melo, L.D., Veiga, P., Cerca, N., Kropinski, A.M., Almeida, C., Azeredo, J., Sillankorva, S., 2016. Development of a phage cocktail to control *Proteus mirabilis* catheter-associated urinary tract infections. *Front. Microbiol.* 7, 1024. <https://doi.org/10.3389/fmicb.2016.01024>

Milo, S., Hathaway, H., Nzakizwanayo, J., Alves, D.R., Esteban, P.P., Jones, B.V., Jenkins, A.T.A., 2017. Prevention of encrustation and blockage of urinary catheters by

Proteus mirabilis via pH-triggered release of bacteriophage. *J. Mater. Chem. B* 5, 5403–5411. <https://doi.org/10.1039/c7tb01302g>

Moraru, C., Varsani, A., Kropinski, A.M., 2020. VIRIDIC—A novel tool to calculate the intergenomic similarities of prokaryote-infecting viruses. *Viruses* 12, 1268. <https://doi.org/10.3390/v12111268>

Murray, C.J.L., Ikuta, K.S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S.C., Browne, A.J., Chipeta, M.G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B.H., Kumaran, E.A.P., McManigal, B., Agarwal, R., Akech, S., Albertson, S., Amuasi, J., Andrews, J., Aravkin, A., Ashley, E., Bailey, F., Baker, S., Basnyat, B., Bekker, A., Bender, R., Bethou, A., Bielicki, J., Boonkasidecha, S., Bukosia, J., Carvalheiro, C., Castañeda-Orjuela, C., Chansamouth, V., Chaurasia, S., Chiurchiù, S., Chowdhury, F., Cook, A.J., Cooper, B., Cressey, T.R., Criollo-Mora, E., Cunningham, M., Darboe, S., Day, N.P.J., De Luca, M., Dokova, K., Dramowski, A., Dunachie, S.J., Eckmanns, T., Eibach, D., Emami, A., Feasey, N., Fisher-Pearson, N., Forrest, K., Garrett, D., Gastmeier, P., Giref, A.Z., Greer, R.C., Gupta, V., Haller, S., Haselbeck, A., Hay, S.I., Holm, M., Hopkins, S., Iregbu, K.C., Jacobs, J., Jarovsky, D., Javanmardi, F., Khorana, M., Kissoon, N., Kobeissi, E., Kostyanev, T., Krapp, F., Krumkamp, R., Kumar, A., Kyu, H.H., Lim, C., Limmathurotsakul, D., Loftus, M.J., Lunn, M., Ma, J., Mturi, N., Munera-Huertas, T., Musicha, P., Mussi-Pinhata, M.M., Nakamura, T., Nanavati, R., Nangia, S., Newton, P., Ngoun, C., Novotney, A., Nwakanma, D., Obiero, C.W., Olivas-Martinez, A., Olliaro, P., Ooko, E., Ortiz-Brizuela, E., Peleg, A.Y., Perrone, C., Plakkal, N., Ponce-de-Leon, A., Raad, M., Ramdin, T., Riddell, A., Roberts, T., Robotham, J.V., Roca, A., Rudd, K.E., Russell, N., Schnall, J., Scott, J.A.G., Shivamallappa, M., Sifuentes-Osornio, J., Steenkeste, N., Stewardson, A.J., Stoeva, T., Tasak, N., Thaiprakong, A., Thwaites, G., Turner, C., Turner, P., van Doorn, H.R., Velaphi, S., Vongpradith, A., Vu, H., Walsh, T., Waner, S., Wangrangsimakul, T., Wozniak, T., Zheng, P., Sartorius, B., Lopez, A.D., Stergachis, A., Moore, C., Dolecek, C., Naghavi, M., 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*. <https://doi.org/10.1016/j.euro.2022.08.023>

Nicolle, L.E., 2014. Catheter associated urinary tract infections. *Antimicrob. Resist. Infect. Control* 3, 1–8. <https://doi.org/10.1186/2047-2994-3-23>

Ondov, B.D., Treangen, T.J., Melsted, P., Mallonee, A.B., Bergman, N.H., Koren, S., Phillippy, A.M., 2016. Mash: fast genome and metagenome distance estimation using MinHash. *Genome Biol.* 17, 1–14. <https://doi.org/10.1186/s13059-016-0997-x>

O’Neill, J., 2014. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. *Rev Antimicrob Resist.*

Ramstedt, M., Ribeiro, I.A., Bujdakova, H., Mergulhão, F.J., Jordao, L., Thomsen, P., Alm, M., Burmølle, M., Vladkova, T., Can, F., 2019. Evaluating efficacy of antimicrobial and antifouling materials for urinary tract medical devices: Challenges and recommendations. *Macromol. Biosci.* 19, 1800384. <https://doi.org/10.1002/mabi.201800384>

Sabir, N., Ikram, A., Zaman, G., Satti, L., Gardezi, A., Ahmed, A., Ahmed, P., 2017. Bacterial biofilm-based catheter-associated urinary tract infections: Causative pathogens and antibiotic resistance. *Am. J. Infect. Control* 45, 1101–1105. <https://doi.org/10.1016/j.ajic.2017.05.009>

Seemann, T., 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–9. <https://doi.org/10.1093/bioinformatics/btu153>

Storms, Z.J., Teel, M.R., Mercurio, K., Sauvageau, D., 2020. The Virulence Index: A Metric for Quantitative Analysis of Phage Virulence. *Phage* 1, 27–36. <https://doi.org/10.1089/phage.2019.0001>

Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect. Dis.* 18, 318–327. [https://doi.org/10.1016/s1473-3099\(17\)30753-3](https://doi.org/10.1016/s1473-3099(17)30753-3)

Tacconelli, E., Magrini, N., Kahlmeter, G., Singh, N., 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. *World Health Organ.* 27.

Terzian, P., Olo Ndela, E., Galiez, C., Lossouarn, J., Pérez Bucio, R.E., Mom, R., Toussaint, A., Petit, M.-A., Enault, F., 2021. PHROG: families of prokaryotic virus proteins clustered using remote homology. *NAR Genomics Bioinforma.* 3, lqab067. <https://doi.org/10.1093/nargab/lqab067>

Townsend, E., Moat, J., Jameson, E., 2020. CAUTI's Next Top Model – model dependent Klebsiella biofilm inhibition by bacteriophages and antimicrobials. *Biofilm BIOFLM\_100038.* <https://doi.org/10.1016/j.bioflm.2020.100038>

Townsend, E.M., Kelly, L., Gannon, L., Muscatt, G., Dunstan, R., Michniewski, S., Sapkota, H., Kiljunen, S.J., Kolsi, A., Skurnik, M., Lithgow, T., Millard, A.D., Jameson, E., 2021. Isolation and Characterization of Klebsiella Phages for Phage Therapy. *PHAGE* 2, 26–42. <https://doi.org/10.1089/phage.2020.0046>

Tsagkari, E., Connelly, S., Liu, Z., McBride, A., Sloan, W.T., 2022. The role of shear dynamics in biofilm formation. *Npj Biofilms Microbiomes* 8, 33. <https://doi.org/10.1038/s41522-022-00300-4>

Wazait, H., Patel, H., Veer, V., Kelsey, M., Van Der Meulen, J., Miller, R., Emberton, M., 2003. Catheter-associated urinary tract infections: prevalence of uropathogens and pattern of antimicrobial resistance in a UK hospital (1996–2001). *BJU Int.* 91, 806–809. <https://doi.org/10.1046/j.1464-410x.2003.04239.x>

Zarb, P., Coignard, B., Griskeviciene, J., Muller, A., Vankerckhoven, V., Weist, K., Goossens, M.M., Vaerenberg, S., Hopkins, S., Catry, B., 2012. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. *Eurosurveillance* 17, 20316.

Fig. 1





Fig. 2

A



B




Fig. 3




Table 1